ArticleLasers in medical science2026
Combined compound betamethasone and 595 nm pulsed dye laser improves hypertrophic scar and is associated with enhanced autophagy in myofibroblasts.
Article in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Compound betamethasone combined with 595 nm pulsed dye laser (PDL) is widely used in the clinical management of hypertrophic scars. However, the mechanisms underlying this enhanced effect remain poorly understood. This study evaluated its therapeutic efficacy and investigated whether induction of autophagy in myofibroblasts is associated with scar improvement. A rabbit ear hypertrophic scar model was established and divided into control, compound betamethasone injection (BI), PDL, and combined (BI + PDL) groups. Scar morphology and histological changes were assessed. Autophagy was evaluated using transmission electron microscopy (TEM) and immunohistochemical detection of LC3B and p62. In vitro, hypertrophic scar-derived myofibroblasts were treated with betamethasone dipropionate (BD), PDL, or their combination (BD + PDL). Cell viability, collagen expression, and autophagic activity were analyzed using CCK-8 assays, Western blotting, MDC staining, immunofluorescence, and TEM. Chloroquine was used to assess autophagic flux. The combined BI + PDL treatment produced the most pronounced improvement in scar architecture, with reduced collagen deposition, decreased microvessel density, and increased number of apoptotic cells. Autophagy levels were significantly elevated in the combination group both in vivo and in vitro. In cultured myofibroblasts, BD + PDL markedly inhibited cell viability and reduced type I and type III collagen expression. This effect was accompanied by increased autophagosome formation, an elevated LC3II/LC3I ratio, and decreased p62 expression. Importantly, inhibition of autophagic flux with chloroquine attenuated the collagen-suppressive effect of the combined treatment. Compound betamethasone combined with 595 nm PDL significantly improves hypertrophic scars, an effect associated with enhanced autophagic activity in myofibroblasts which may partly mediate collagen degradation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.